The US Food and Drug Administration (FDA) has approved a generic version of Roche Holding’s oral chemotherapy pill, Xeloda (capecitabine).
Xeloda is used to treat colorectal cancer that has spread to other parts of the body (metastatic) as well as metastatic breast cancer.
Go deeper with GlobalData
As part of the approval, Teva Pharmaceuticals USA will be responsible for marketing the generic version of Xeloda in 150mg and 500mg doses.
FDA Center for Drug Evaluation and Research’s acting director of Office of Generic Drugs Kathleen Uhl said: "This medication is widely used by people living with cancer, so it is important to have access to affordable treatment options."
Common adverse events seen in clinical trials for Xeloda include diarrhea, vomiting, and nausea, as well as oral pain, redness, swelling, and sores, while other events were hand-foot syndrome, fever and infection.
According to FDA, it is important that the prescriber know if the patient is also taking a medicine used to thin the blood, such as warfarin.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSee Also:
The drug is packaged with a boxed warning to avoid co-treatment with blood thinners, which may cause serious adverse events.
Generic drug manufacturing and packaging sites must pass the same quality standards as those of brand-name drugs since generics possess the same quality and strength as brand-name drugs.
Image: A micrograph of an invasive cecal adenocarcinoma. Photo: courtesy of Nephron.
